Close

Anti-CD33 (Gemtuzumab) h(CD3ζ, TetR/Tip) Conditional CAR, pCDCAR1 (CAR-LC280)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-CD33 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD33. The T cells are genetically modified through transduction with a lentiviral vector expressing a bicistronic construct which self-cleaves at the 2A site to yeild TiP fused to CD3ζ signaling domain and a 1st generation CD33 CAR with TetR as its endodomain. The CAR-T function can be controlled by tetracycline through competitive binding of TetR with Tip. And the vector product was designed for the treatment of acute lymphoid leukemia.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CD33
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Acute lymphoid leukemia
  • Generation
  • First
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • scFv-TetR/Tip-CD3ζ
  • Discription of Signaling Cassetes
  • CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • Gemtuzumab
  • Host
  • Human
  • Target Species
  • Human
  • Gene Name
  • CD33
  • Synonyms
  • CD33;CD33; CD33 Molecule; CD33 Molecule; Sialic Acid-Binding Ig-Like Lectin 3; CD33 Antigen (Gp67); SIGLEC-3; SIGLEC3; Gp67;

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data FCM

Fig.1 Flow cytometry analysis.

CAR Construction : Gemtuzumab scFv-41BB-CD28ζ Latest CAR Construction

Fig.1 Flow cytometry analysis.

Flow cytometry analysis of protein L expression demonstrating transduction efficiency of T cells transduced with gemtuzumab-based (gem), lintuzumab-based (lin), and M195-based CD33 CAR constructs or CD123 CAR constructs.

Qin, H., Yang, L., Chukinas, J. A., Shah, N., Tarun, S., Pouzolles, M., Chien, C. D., Niswander, L. M., Welch, A. R., Taylor, N., Tasian, S. K., & Fry, T. J. (2021). Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design. Journal for immunotherapy of cancer, 9(9), e003149.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD33 (Gemtuzumab) h(CD3ζ, TetR/Tip) Conditional CAR, pCDCAR1 (CAR-LC280). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.